Biberoglu Ebru H, Tanrıkulu Filiz, Erdem Mehmet, Erdem Ahmet, Biberoglu Kutay Omer
a Dr. Zekai Tahir Burak Women Health Care, Education and Research Hospital , Ankara , Turkey .
b Araklı Bayram Halil Hospital , Trabzon , Turkey , and.
Gynecol Endocrinol. 2016;32(1):55-7. doi: 10.3109/09513590.2015.1077382. Epub 2015 Aug 18.
Vaginal progesterone (P) has been suggested to be used for luteal phase support (LPS) in controlled ovarian stimulation (COH)-intrauterine insemination (IUI) cycles, however, no concensus exists about the best P dose. Therefore, considering the fecundability rate as the primary end point, our main objective was to find the optimal dose of P in COH-IUI cycles, comparing the two groups of women, each of which comprised of 100 women either on 300 mg or 600 mg of intravaginal P tablets, in a prospective randomized study design. The mean age of the women, duration of infertility, basal and day of hCG injection hormone levels in the female and sperm parameters were similar in the two study groups. Also, duration and dose of gonadotropin given, number of follicles, endometrial thickness, the total, ongoing and multiple pregnancy rates were comparable in both groups. We, therefore, claim that 300 mg of intravaginal micronized P should be the maximum dose of LPS in IUI cycles.
阴道内使用黄体酮(P)已被建议用于控制性卵巢刺激(COH)-宫内人工授精(IUI)周期的黄体期支持(LPS),然而,关于最佳P剂量尚无共识。因此,以前瞻性随机研究设计,将可受孕率作为主要终点,我们的主要目标是在COH-IUI周期中找到P的最佳剂量,比较两组女性,每组100名,分别使用300mg或600mg阴道内用P片。两个研究组中女性的平均年龄、不孕持续时间、女性基础激素水平及hCG注射日的激素水平和精子参数相似。此外,两组中促性腺激素的给药持续时间和剂量、卵泡数量、子宫内膜厚度、总妊娠率、持续妊娠率和多胎妊娠率相当。因此,我们认为300mg阴道内用微粉化P应是IUI周期中LPS的最大剂量。